The peroxisome proliferator‐activated receptors in cardiovascular diseases: experimental benefits and clinical challenges

@article{Cheang2015ThePP,
  title={The peroxisome proliferator‐activated receptors in cardiovascular diseases: experimental benefits and clinical challenges},
  author={W. Cheang and X. Tian and W. Wong and Yu Huang},
  journal={British Journal of Pharmacology},
  year={2015},
  volume={172}
}
The peroxisome proliferator‐activated receptors, PPARα, PPARβ/δ and PPARγ, are ligand‐activated transcriptional factors belonging to the nuclear receptors superfamily and they are known to play important roles in glucose and lipid metabolism. Experimental studies in animal models of metabolic diseases have also revealed that activation of PPARs protects against the vascular complications of diabetes, hypertension, atherosclerosis, myocardial infarction and stroke, through exerting their anti… Expand
Antihypertensive effects of peroxisome proliferator-activated receptor-β/δ activation.
TLDR
Preclinical studies suggest that pharmacological PPARβ/δ activation induces antihypertensive effects in direct and indirect models of hypertension, associated with end-organ damage protection and evidence from clinical trials is examined. Expand
The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development
TLDR
84 types of PPAR synthetic ligands introduced to date for the treatment of metabolic and other diseases are summarized and a comprehensive analysis of the current applications and problems of these ligands in clinical drug discovery and development is provided. Expand
The Positive Regulation of eNOS Signaling by PPAR Agonists in Cardiovascular Diseases
TLDR
The most meaningful and up-to-date in vitro and in vivo studies of the regulation of NO production performed by different PPAR agonists are reported, providing insights into the molecular mechanisms of PPAR-mediated eNOS activation. Expand
Peroxisome proliferator‐activated receptors in cardiac energy metabolism and cardiovascular disease
TLDR
The role of isoforms of PPAR in the cardiomyocytes energy balance and CVD is discussed in the hope that the knowledge will help in the synthesis of ligands for their partial activation in order to render energy Balance and protection from CVD. Expand
Myeloid peroxisome proliferator-activated receptor gamma deficiency aggravates myocardial infarction in mice.
TLDR
Myeloid Pparγ deficiency exacerbates MI, likely through increased oxidative stress and cardiac inflammation, and MPGKO mice had worsen cardiac dysfunction after MI. Expand
Pharmacological Activation of Peroxisome Proliferator-Activated Receptor {Delta} Increases Sphingomyelin Synthase Activity in THP-1 Macrophage-Derived Foam Cell
TLDR
This study represents the first to suggest that PPARδ activation may be a potential risk of AS through enhancing activity of SMS2 through the influence of GW501516 on SMS and its product molecule SM. Expand
Study of the interactions between Edaglitazone and Ciglitazone with PPAR&ggr; and their antiplatelet profile
TLDR
It is evidenced that Edaglitazone increases intraplatelet cAMP levels and prevents PPAR&ggr; secretion, explaining its greater antiplatelet activity. Expand
PPAR-γ Agonists and Their Role in Primary Cicatricial Alopecia
TLDR
A focus on PPAR-γ involvement in pathogenesis of lichen planopilaris (LPP), the most common lymphocytic form of PCA, is discussed and clinical trials utilizing PPar-agonists in PCA treatment are discussed. Expand
Peroxisome proliferator-activated receptor-α stimulation by clofibrate favors an antioxidant and vasodilator environment in a stressed left ventricle.
TLDR
Clofibrate-induced PPAR-α stimulation changes the angiotensin II receptor profile, favors the ACE2/angiotens in-(1-7)/AT2 receptor axis decreasing the vasoconstrictor environment, activates the antioxidant defense, and facilitates endothelial nitric oxide synthase activity favoring vasodilation. Expand
A novel small-molecule agonist of PPAR-γ potentiates an anti-inflammatory M2 glial phenotype
TLDR
A hit compound containing N-carbamoylated urethane moiety (SNU-BP) exhibited an anti-inflammatory effect in the LPS-injected mouse brain, demonstrating a protective potential for neuroinflammatory diseases. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 122 REFERENCES
PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome
TLDR
Future development of dual PPARalpha/gamma agonists with selective PPAR modulator activity appears appropriate and should be feasible. Expand
PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
TLDR
Future development of dual PPARalpha/gamma agonists with selective PPAR modulator activity appears appropriate and should be feasible. Expand
The PPAR-RXR Transcriptional Complex in the Vasculature: Energy in the Balance
  • J. Plutzky
  • Biology, Medicine
  • Circulation research
  • 2011
TLDR
Detailed data establishing a key role for PPARs and RXRs in energy balance, inflammation, and vascular biology stands separately from the clinical experience with any given synthetic PPAR agonist. Expand
Interference with PPAR gamma function in smooth muscle causes vascular dysfunction and hypertension.
TLDR
Results identify PPARgamma as pivotal in vascular muscle as a regulator of vascular structure, vascular function, and blood pressure, potentially explaining some of the cardioprotective effects of thiazolidinediones. Expand
PPARδ regulates multiple proinflammatory pathways to suppress atherosclerosis
TLDR
It is shown here that orally active PPARδ agonists significantly reduce atherosclerosis in apoE−/− mice and suggest PParδ-selective drugs as candidate therapeutics for Atherosclerosis. Expand
Three-in-one agonists for PPAR-α, PPAR-γ, and PPAR-δ from traditional Chinese medicine
TLDR
The top two TCM candidates are proposed as potential lead compounds in developing agonists targeting PPARs protein for treating metabolic syndrome. Expand
Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity
TLDR
It is shown here that targeted activation of PPARδ in adipose tissue specifically induces expression of genes required for fatty acid oxidation and energy dissipation, which in turn leads to improved lipid profiles and reduced adiposity. Expand
Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.
TLDR
The AleCardio trial examines whether the addition of aleglitazar to standard medical therapy reduces the risk of cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus and recent acute coronary syndrome. Expand
The Peroxisome Proliferator Activated Receptor‐γ Pioglitazone Improves Vascular Function and Decreases Disease Activity in Patients With Rheumatoid Arthritis
TLDR
Addition of pioglitazone to RA standard of care significantly improves aortic elasticity and decreases inflammation and disease activity with minimal safety issues. Expand
Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity.
TLDR
It is shown here that targeted activation of PPARdelta in adipose tissue specifically induces expression of genes required for fatty acid oxidation and energy dissipation, which in turn leads to improved lipid profiles and reduced adiposity. Expand
...
1
2
3
4
5
...